SEARCH · Search PubMed

Results for “VCP”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

295 records · Page 17Linked to original sources

PubMed2004

Paper mill wastewater detoxification by solar photocatalysis.

In the WATER project the German Aerospace Center, and the Universidade Federal de Uberlândia, analyse the possibilities of treating paper mill effluents by solar photocatalysis for the paper mill of the Brazilian paper producer Votorantim Celulose e Papel, VCP, at Luiz Antônio, SP, Brazil. The degradation of the bio-polymer lignin is a vast problem in paper production. The tests have shown that treatment by the photocatalyst TiO2 and solar radiation is an ecological future oriented approach to solve this problem. The treatment of lignin containing process water by solar photocatalysis was optimised and the economics for solar treatment plants of different sizes was estimated to check the possibilities for implementing the technology in industrial processes.

Catalysis↗

PubMedDate not supplied

Gateways to clinical trials.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate; ACP-103, Ad.Egr.TNF.11 D, adalimumab, AF-IL 12, AIDSVAX gp120 B/B, alefacept, alemtuzumab, a-Galactosylceramide, ALVAC vCP 1452, alvimopan hydrate, alvocidib hydrochloride, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anidulafungin, antarelix, aprepitant, aripiprazole, arsenic sulfide, asoprisnil, atazanavir sulfate, atomoxetine hydrochloride; Bevacizumab, bimatoprost, BMS-184476, bortezomib, bosentan, botulinum toxin type B, BrachySil, brivudine; Caffeine, calcipotriol/betamethasone dipropionate, cannabidiol, capsaicin for injection, caspofungin acetate, CC-4047, cetuximab, CGP-36742, clofazimine, CpG-7909, Cypher; Darbepoetin alfa, dextromethorphan/quinidine sulfate, dimethylfumarate, dronabinol/cannabidiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, eletriptan, emtricitabine, enfuvirtide, eplerenone, esomeprazole magnesium, estradiol acetate, eszopiclone, etoricoxib, exenatide, ezetimibe, ezetimibe/simvastatin; Fampridine, fondaparinux sodium, fosamprenavir calcium; Gefitinib, GPI-0100; hA 20, HTU-PA, human insulin, HuOKT 3 gamma 1(Ala 234-Ala 235), hyaluronic acid; Icatibant, imatinib mesylate, Indiplon, INKP-100, INKP-102, iodine (I131) tositumomab, istradefylline, IV gamma-globulin, ivabradine hydrochloride, ixabepilone; Lacosamide, landiolol, lanthanum carbonate, lasofoxifene tartrate, LB-80380, lenalidomide, lidocaine/tetracaine, linezolid, liposomal doxorubicin, liposomal vincristine sulfate, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Maribavir, morphine glucuronide, MVA-5 T 4; NBI-56418, NCX-4016, nesiritide, nicotine conjugate vaccine, NSC-330507; Oglufanide, omalizumab, oxipurinol; Palifermin, palonosetron hydrochloride, parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, PEGylated interferon alfacon-1, perospirone hydrochloride, pimecrolimus, pixantrone maleate, plerixafor hydrochloride, PowderJect lidocaine, pradefovir mesylate, prasterone, pregabalin, Prostvac VF, PT-141, PTC-124, pyridoxamine; QS-21, quercetin; R-126638, R-411, ralfinamide, rasagiline mesilate, rF-PSA, RG-2077, rhThrombin, rimonabant hydrochloride, rofecoxib, rosuvastatin calcium, rotigotine hydrochloride, rV-PSA; S-18886, S-303, seocalcitol, SGN-40, sitaxsentan sodium, SPP-301, St. John's Wort extract; Tadalafil, taxus, telithromycin, tenatoprazole, tenofovir disoproxil fumarate, testosterone MDTS, testosterone transdermal patch, tgAAC-09, TH-9507, thioacetazone, tipifarnib, TQ-1011, trabectedin, travoprost, trimethoprim; Valdecoxib, valganciclovir hydrochloride, valopicitabine, voriconazole; Xcellerated T cells.

Clinical Trials as Topic↗

PubMed2006

The Candida albicans AAA ATPase homologue of Saccharomyces cerevisiae Rix7p (YLL034c) is essential for proper morphology, biofilm formation and activity of secreted aspartyl proteinases.

Proper morphology is essential for the ability of Candida albicans to switch between yeast and hyphae and thereby sustain its virulence. Here we identified, by differential screening, a novel C. albicans AAA ATPase encoding gene, CaYLL34 (RIX7), with enhanced expression in hyphae. Phylogenetic analysis suggests that CaYLL34 belongs to a "VCP-like" subgroup of AAA ATPases essential for yeast viability and contains a bipartite nuclear localization signal. Inactivation of one copy of CaYLL34, by the URA-Blaster method, generated the heterozygous mutant strain M61. This strain has severe phenotypic alterations, such as a highly increased vacuole, abnormal cell shape and reduced growth in different conditions. Also, major pathogenicity factors are affected in M61, for instance, a significant decrease of hypha formation (>90%), surface biofilm adhesion (86%) and secreted aspartyl proteinase activity (76.5%). Our results show that the partial impairment of CaYll34p cellular levels is sufficient to affect the proper cellular morphology and pathogenicity factors and suggest that this protein is required for biogenesis of ribosomal subunits. Accordingly, we propose that the product of CaYLL34 could be tested as a novel target for antifungal drugs.

Adenosine Triphosphatases↗

PubMed1989

[Cancer curable by chemotherapy: malignant lymphoma].

The trends in the rationale of chemotherapy for malignant lymphoma are to use combination regimen, non-cross resistant alternating regimen, and hybrid regimen. Long follow-up results of chemotherapy of lymphoma were summarized as follows: for Hodgkin's disease, MOPP regimen of 20 years from NCI in 188 patients (pts) with 84% CR rate and 54% (101 pts) relapse-free (RF) at 15 years, and MOPP-ABV hybrid regimen in 76 pts with 97% CR rate and 90% RFS rate at 7 years; for non-Hodgkin's lymphoma (NHL), results of three generations are reported: the first generations were the first generation (CHOP, BACOP, 40-50s% CR rate and 30s% long-term survivors), the second generation (Pro-MACE/MOPP, 70s% and 40-50s%) and the third generation (MACOP-B, 80s% and 60-70s%). MACOP-B regimen in 125 pts with large-cell lymphoma showed 84% CR rate and 69% RFS rate and 69% RFS rate at 6.5 years. In our studies with four regimens of VCP, AVCP, AVCP/EMLP and B-AVCR/EMVP, CR rate was 56% in 101 pts, and 26 pts are still in CR among 40 living pts. The CR rate and the RSF rate reported in Japan are generally still low for curability of NHL.

Antineoplastic Combined Chemotherapy Protocols↗

PubMed1983

[Adjuvant chemotherapy for localized non-Hodgkin's lymphoma with CVP therapy].

Fifty-two patients with localized (stage I-II) non-Hodgkin's lymphoma were treated with a combination of vincristine, cyclophosphamide and prednisolone (VCP) as an adjuvant therapy between 1975 and 181. Forty-two patients had extended-field radiotherapy, and ten patients had only surgical excision (6 gastrointestinal tract, 2 breast, one each of skin and axillary lymph node). Clinical stages of these patients were divided into stage I (21 patients) and stage II (31 patients). With a median follow-up time of relapse-free survival (RFS) were calculated by Kaplan and Meier method. At two years after the initiation of chemotherapy, survival and RFS were 95% and 83% for stage I, and 76% and 74% for stage II, respectively. These ratios remained stable for 7 years. Survival and RFS of diffuse histiocytic lymphoma (34 patients) were 90% and 83% at 7 years, while these of diffuse poorly differentiated lymphocytic lymphoma (18 patients) were 75% and 69% at 4 years. Of 52 patients, 10 had relapsed (Stage I: 3 patients and stage II: 7 patients) within the first 2 years. Side effect was minimal with moderate peripheral neuropathy due to vincristine. The result suggests that adjuvant chemotherapy is necessary to improve prognosis of patients with localized non-Hodgkin's lymphoma.

Antineoplastic Combined Chemotherapy Protocols↗

PubMed1996

[The use of the veterinary cuttable plate in 160 cases].

The use of the Veterinary Cuttable Plate (VCP) is described using the experience in 160 cases. The range of its use and the technique of application is shown in cats and small, medium sized and large dogs, and complications are discussed.

Animals↗

PubMed2026

Selenoprotein S associates with complexes governing membrane protein biogenesis and translation-associated processes.

Human selenoprotein S (selenos) is part of the integrated cellular stress response and linked to protein quality control and signaling pathways. Consequently, genetic polymorphisms of selenos are associated with increased risks for diabetes, dyslipidemia, and cardiovascular diseases. Determining the specific roles of selenos in these cellular pathways and diseases has been challenging, as selenos associates with a wide range of protein complexes. Thus, to map the cellular functions of selenos and uncover their interconnections, we used affinity purification and in vivo crosslinking to stabilize transient protein interactions, followed by proteomics to record the resulting selenos interactome. Through mapping of selenos protein partners, we found evidence that selenos associates with complexes responsible for the insertion of membrane proteins into the endoplasmic reticulum (ER) bilayer and their connected quality control components. Furthermore, selenos is also part of metabolic, trafficking, and mitochondrial pathways. Notably, proteins involved in translation preferentially associate with selenos when its C-terminal intrinsically disordered segment containing the redox-active motif is accessible. Together, these results identify the C-terminal redox loop of selenos as a central interaction hub connecting translation with ER membrane protein biogenesis and quality control.

Selenoproteins↗